Prevalence of children born small for gestational age with short stature who qualify for growth hormone treatment

BACKGROUND: Recombinant human growth hormone (rhGH) is approved in Europe as a treatment for short children born small for gestational age (SGA) since 2003. However, no study evaluated the prevalence of SGA children with short stature who qualify for rhGH in Europe so far. This study aimed to invest...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ital J Pediatr
Main Authors: Tamaro, Gianluca, Pizzul, Mariagrazia, Gaeta, Giuliana, Servello, Raffaella, Trevisan, Marina, Böhm, Patricia, Materassi, Paola Manera Ada, Macaluso, Anna, Valentini, Denis, Pellegrin, Maria Chiara, Barbi, Egidio, Tornese, Gianluca
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8015030/
https://ncbi.nlm.nih.gov/pubmed/33794966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13052-021-01026-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados